N,N-dimethyl-5-((2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yl)oxy)pyrimidine-2-carboxamide
- Product Name
- N,N-dimethyl-5-((2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yl)oxy)pyrimidine-2-carboxamide
- CAS No.
- 1245603-92-2
- Chemical Name
- N,N-dimethyl-5-((2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yl)oxy)pyrimidine-2-carboxamide
- Synonyms
- EOS-61370;PF-04937319;PF-04937319[PZ0320];PF-04937319 >=98% (HPLC);Nerigliatin (PF-04937319);PF-04937319, 10 mM in DMSO;Inhibitor,PF-04937319,Hexokinase IV,PF 04937319,PF04937319,Hexokinase D,inhibit,Glucokinase;N,N-dimethyl-5-((2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yl)oxy)pyrimidine-2-carboxamide;N,N-Dimethyl-5-[2-methyl-6-[N-(5-methylpyrazin-2-yl)carbamoyl]-1-benzofuran-4-yloxy]pyrimidine-2-carboxamide;N,N-Dimethyl-5-[[2-methyl-6-[[(5-methyl-2-pyrazinyl)amino]carbonyl]-4-benzofuranyl]oxy]-2-pyrimidinecarboxamide
- CBNumber
- CB93143080
- Molecular Formula
- C22H20N6O4
- Formula Weight
- 432.43
- MOL File
- 1245603-92-2.mol
N,N-dimethyl-5-((2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yl)oxy)pyrimidine-2-carboxamide Property
- Density
- 1.366±0.06 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- Soluble in DMSO
- form
- Solid
- pka
- 10.41±0.70(Predicted)
- color
- White to yellow
N-Bromosuccinimide Price
- Product number
- 6049
- Product name
- PF04937319
- Purity
- ≥98%(HPLC)
- Packaging
- 5
- Price
- $72
- Updated
- 2021/12/16
- Product number
- 6049
- Product name
- PF04937319
- Purity
- ≥98%(HPLC)
- Packaging
- 25
- Price
- $302
- Updated
- 2021/12/16
- Product number
- P294120
- Product name
- PF04937319
- Packaging
- 1mg
- Price
- $90
- Updated
- 2021/12/16
- Product number
- CS-0028321
- Product name
- PF-04937319
- Purity
- >99.0%
- Packaging
- 5mg
- Price
- $230
- Updated
- 2021/12/16
- Product number
- CS-0028321
- Product name
- PF-04937319
- Purity
- >99.0%
- Packaging
- 1mg
- Price
- $75
- Updated
- 2021/12/16
N,N-dimethyl-5-((2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yl)oxy)pyrimidine-2-carboxamide Chemical Properties,Usage,Production
Uses
Nerigliatin (PF-04937319) is a orally active glucokinase activator (GKA) with EC50 value of 154.4 μM. Nerigliatin maintains glucose-lowering efficacy. Nerigliatin causes peripheral nerve degeneration. Nerigliatin can be used in type 2 diabetes research.
Biological Activity
PF-04937319 is a glucokinase activator with an EC50 value of 174 nM. PF-04937319 was found to improve glycemic control in adults with type 2 diabetes when used in conjunction with metformin.', 'PF-04937319, unlike other glucokinase activators, is capable of maintaining lower-glucose levels without it resulting in hypoglycemia. In type II diabetic patients where metformin treatment is inadequate, PF-04937319 is capable of maintaining glycemic control within the acceptable risk-benefit profile.
in vivo
Nerigliatin (males: 50-1000 mg/kg; females: 10-1000 mg/kg; p.o.; once daily; 1 month) causes axonal degeneration in the peripheral (sciatic) nerve of female rats[4].
Nerigliatin (5-500 mg/kg; p.o.; once daily; 1 month) leads to peripheral nerve degeneration and unscheduled deaths in dogs[4].
| Animal Model: | Sprague-Dawley rats (male and female, 10 weeks of age), beagle dogs (male and female, 8-12 months old)[4] |
| Dosage: | Rats-males: 50, 250, 1000 mg/kg; females: 10, 50, 1000 mg/kg (suspended in 1.25% hydroxypropyl cellulose and 0.5% docusate sodium); Dogs-males and females: 5, 50, 500 mg/kg (suspended in 1.25% hydroxypropyl cellulose and 0.5% docusate sodium) |
| Administration: | Rats-oral gavage, once daily, 1 month; Dogs-oral gavage, once daily, 1 month |
| Result: | Caused axonal degeneration in the peripheral (sciatic) nerve of female rats at 50 and 1000 mg/kg in Sprague- Dawley rats. Led to peripheral nerve degeneration in some animals at 50 and 500 mg/kg, and 2 unscheduled deaths occurred at 500 mg/kg/day in beagle dogs. |
References
[1] Dzyurkevich MS, et al. Pyridoxine dipharmacophore derivatives as potent glucokinase activators for the treatment of type 2 diabetes mellitus. Sci Rep. 2017 Nov 22;7(1):16072. DOI:10.1038/s41598-017-16405-2
[2] Amin NB, et al. Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes. Diabetes Obes Metab. 2015 Aug;17(8):751-9. DOI:10.1111/dom.12474
[3] Sharma R, et al. Metabolites in safety testing assessment in early clinical development: a case study with a glucokinase activator. Drug Metab Dispos. 2014 Nov;42(11):1926-39. DOI:10.1124/dmd.114.060087
[4] Pettersen JC, et al. The relationship of glucokinase activator-induced hypoglycemia with arteriopathy, neuronal necrosis, and peripheral neuropathy in nonclinical studies. Toxicol Pathol. 2014 Jun;42(4):696-708. DOI:10.1177/0192623314526006
N,N-dimethyl-5-((2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yl)oxy)pyrimidine-2-carboxamide Preparation Products And Raw materials
Raw materials
Preparation Products
N,N-dimethyl-5-((2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yl)oxy)pyrimidine-2-carboxamide Suppliers
- Tel
- --
- Fax
- --
- customerservice@tocris.co.uk
- Country
- United Kingdom
- ProdList
- 5726
- Advantage
- 77